CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 24.9% in August

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant decline in short interest in August. As of August 15th, there was short interest totaling 35,600 shares, a decline of 24.9% from the July 31st total of 47,400 shares. Based on an average trading volume of 64,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.6% of the company’s stock are sold short. Currently, 0.6% of the company’s stock are sold short. Based on an average trading volume of 64,900 shares, the days-to-cover ratio is presently 0.5 days.

CalciMedica Stock Up 15.9%

Shares of CalciMedica stock opened at $3.58 on Wednesday. CalciMedica has a twelve month low of $1.42 and a twelve month high of $5.65. The stock has a market capitalization of $50.02 million, a price-to-earnings ratio of -2.24 and a beta of 1.32. The business’s 50 day simple moving average is $2.79 and its 200-day simple moving average is $2.16. The company has a current ratio of 5.45, a quick ratio of 5.45 and a debt-to-equity ratio of 1.39.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). Equities research analysts forecast that CalciMedica will post -2.21 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of CalciMedica in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $16.00.

Insider Activity

In other CalciMedica news, insider Sudarshan Hebbar purchased 9,563 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The shares were acquired at an average price of $2.82 per share, for a total transaction of $26,967.66. Following the completion of the purchase, the insider owned 61,539 shares in the company, valued at $173,539.98. The trade was a 18.40% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric W. Roberts acquired 9,200 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were purchased at an average price of $2.86 per share, for a total transaction of $26,312.00. Following the purchase, the insider directly owned 70,107 shares of the company’s stock, valued at $200,506.02. This represents a 15.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 68,623 shares of company stock worth $176,940. Insiders own 41.55% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CALC. First Manhattan CO. LLC. bought a new position in CalciMedica during the 1st quarter valued at $25,000. 180 Wealth Advisors LLC purchased a new stake in shares of CalciMedica in the first quarter valued at $31,000. Sound View Wealth Advisors Group LLC purchased a new stake in shares of CalciMedica in the second quarter valued at $32,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of CalciMedica in the first quarter valued at $45,000. Finally, Cetera Investment Advisers raised its holdings in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after acquiring an additional 9,045 shares in the last quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.